Created at Source Raw Value Validated value
Dec. 3, 2020, 12:31 a.m. usa

- hypersensitivity to any component of bcg-10 - hypersensitivity to previously administered tuberculin (local skin lesions, necrosis of the skin, blisters, other severe skin reactions at the injection site) - hiv infection (confirmed or suspected infections, even if they are asymptomatic) - primary or secondary immunodeficiencies (including interferon - gamma deficiency or digeorge syndrome) - radiotherapy (less than 24 months before the date of inclusion in the trial - treatment with corticosteroids, ongoing immunosuppressive therapy (including those treated with monoclonal antibodies to tnf-α, such as infliximab) - less than 24 months before the date of inclusion in the trial - neoplastic diseases (e.g. leukaemia, malignant granuloma, lymphoma or some other cancer of the reticuloendothelial system) - less than 24 months before the date of inclusion in the study - after stem cell transplantation and organ transplantation - in the exacerbation stage of chronic diseases (including severe malnutrition) - pregnancy - history of tuberculosis - keloid at the vaccination site after previous bcg vaccination

- hypersensitivity to any component of bcg-10 - hypersensitivity to previously administered tuberculin (local skin lesions, necrosis of the skin, blisters, other severe skin reactions at the injection site) - hiv infection (confirmed or suspected infections, even if they are asymptomatic) - primary or secondary immunodeficiencies (including interferon - gamma deficiency or digeorge syndrome) - radiotherapy (less than 24 months before the date of inclusion in the trial - treatment with corticosteroids, ongoing immunosuppressive therapy (including those treated with monoclonal antibodies to tnf-α, such as infliximab) - less than 24 months before the date of inclusion in the trial - neoplastic diseases (e.g. leukaemia, malignant granuloma, lymphoma or some other cancer of the reticuloendothelial system) - less than 24 months before the date of inclusion in the study - after stem cell transplantation and organ transplantation - in the exacerbation stage of chronic diseases (including severe malnutrition) - pregnancy - history of tuberculosis - keloid at the vaccination site after previous bcg vaccination